CASP1 and rheumatoid arthritis: VX-765 is structurally similar to VX-740, acting by covalent modification of the catalytic cysteine residues in the caspase-1 active site, which has been tested in phase II trials for psoriasis and epilepsy, but not yet in rheumatoid arthritis (112, 113).